The FDA peptide meeting is coming. Here's what a "yes" actually buys.
On July 23–24, 2026, an FDA advisory committee reviews seven peptides. A lot of the internet is treating that date like a finish line. It's a starting line, and the difference matters before you trust anyone selling these today.
What PCAC is
The Pharmacy Compounding Advisory Committee (PCAC) is a federal advisory committee. It reviews substances and makes recommendations, and those recommendations are non-binding. The FDA decides what to do with them.
The seven under review
July 23, 2026
July 24, 2026
BPC-157 · KPV · TB-500 · MOTS-c
Emideltide (DSIP) · Semax · Epitalon
What happens after a "yes"
Recommendation, PCAC votes to recommend a substance for the 503A bulks list.
FDA rulemaking, a proposed rule, a public-comment window, then a final rule.
Only then can a 503A pharmacy compound it. Realistic timeline: 2027.
Category 1 ≠ FDA approval
Category 1 means a substance can be compounded under interim policy with clinical oversight. It does not mean the substance went through FDA drug approval. Compounded medications are not FDA-evaluated for safety, efficacy, or quality.
What the internet gets wrong
Sites claiming these peptides are "Category 1 now" or "available after July" are wrong, and that's exactly the kind of claim our FDA Tracker exists to neutralize. Reclassification is not the same as FDA approval, and a PCAC recommendation is not availability.
Questions, answered
The honest answers.
The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviews seven peptides on July 23–24, 2026. It is advisory: a favorable vote leads to rulemaking, not instant availability.
Not automatically. A favorable PCAC vote starts an FDA rulemaking process, proposed rule, public comment, final rule, that realistically runs into 2027 before a 503A pharmacy could compound it. We'll publish each step on the Tracker.
No. A recommendation is non-binding and is not approval or availability. We won't sell anything until it legitimately clears and fulfillment through a licensed pharmacy is confirmed.
Medically reviewed by the Peptós.LIFE clinical team · Last reviewed Jun 2026 · Sources on file. Educational content, not medical advice. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality. Reclassification is not the same as FDA approval.